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ABSTRACT
Objectives: Agomelatine is a novel melatonin (MT) receptor agonist at MT 1 and 2, serotonin receptor antagonist and an effective chronobiotic agent. 
The study was designed to evaluate the effects of agomelatine on body weight and food intake in restraint stress model in adult Swiss albino mice.
Methods: After the approval of Institutional Animal Ethics Committee, 40 male Swiss albino mice were randomly divided into four groups of 
10 animals each; two were treatment groups which received 25 mg/kg (low dose) agomelatine, 50 mg/kg (high dose) agomelatine, standard group 
given trazodone and the control group administered the vehicle (1% hydroxyethyl cellulose [HEC]) intraperitoneally for the last 14 days in the 3 weeks 
study period. Chronic restraint stress was given for 4 hrs per day for all groups starting from day 0 to 21.
Results: Using paired t-test, both 12 hrs (p=0.011) and 24 hrs (p<0.001) food intake in the high dose agomelatine group were significantly increased. 
Between groups  using ANOVA test showed a statistically significant increase in food intake for this group when compared to the control group. Unlike 
the low dose agomelatine group (p=0.205), the mean body weight in the group treated with high dose agomelatine revealed a statistically significant 
rise compared to that of the control (p=0.001) in ANOVA test.
Conclusion: High dose agomelatine was effective in antagonizing the body weight lowering effect of restraint stress in addition to amelioration of 
reduced food intake. The study has potentially brought out the additional therapeutic benefit of agomelatine in improving the altered feeding and 
body weight changes when used in the treatment of the depression.
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INTRODUCTION
Depression is a common illness worldwide, with an estimated 
350 million people affected; constituting a major portion of mental 
health disorders [1]. A meta-analysis reported that the worldwide 
prevalence rate of depressive disorders in elderly population 
between 4.7% and 16% with a comparatively higher prevalence of 
21.9% in India [2]. A study conducted in North India has shown that 
the prevalence of depression in the elderly was high even in a rural 
community with an estimate of 14.4% [3]. Hamilton Rating Scale for 
depression states that key features of depression include weight loss 
and reduced appetite [4]. Core symptoms according to diagnostic and 
statistical manual of mental disorders-V also includes eating too much/
little. Moreover a U-shaped association between body weight and 
depression has been described [5].
Agomelatine is a novel melatonin (MT) receptor agonist at MT1 and 
MT2 receptors, serotonin receptor 5-hydroxytryptamine (5HT32C) 
antagonist and an effective chronobiotic agent. It is found to be an 
effective antidepressant and an anxiolytic agent [6,7]. It has also been 
proved to improve sleep in a depressed patient by synchronizing the 
circadian rhythm [7].
Agomelatine, in addition to being a chronobiotic agent, has been 
shown to be effective in restraint stress induced depression in animal 
models [8]. Chronic restraint stress induces depressive-like behavior by 
increasing immobility time in the forced swimming test and cognitive 
deficit by producing memory impairment in the object recognition 
testing in animal models [9]. Restraint stress also affects the food 
intake and body weight of the animals [10]. There is a paucity of studies 
evaluating the effects of agomelatine on body weight and food intake 
in depression. Therefore the study was designed to evaluate the effects 
of agomelatine on body weight and food intake in restraint stress 
(immobility induced) model in adult Swiss albino mice.
METHODS
The Institutional Animal Ethics Committee approved the protocol of the 
study (Approval number: 241/2014/IAEC). Adult, male Swiss albino 
mice weighing 25-40 g and aged 5-10 months were housed in constant 
ambient temperature under 12 hrs light, 12 hrs dark cycle. They were 
group housed as 3-4 mice per cage in polypropylene cages. Pellet diet 
and tap water were provided ad libitum. The animals were randomly 
allocated into four groups of 10 mice per group.
•	 Group	 1	 -	 (treatment	 Group	 1)	 low	 dose	 agomelatine	 was	
administered - 25 mg/kg/day
•	 Group	 2	 -	 (treatment	 Group	 2)	 high	 dose	 agomelatine	was	
administered - 50 mg/kg/day
•	 Group	3	-	(standard	group)	trazodone	10	mg/kg/day
•	 Group	4	-	control	group	given	1%	HEC.
The vehicle HEC is cellulose derived hydrophilic polymer [11]. The test, 
standard and vehicle (1% HEC) were given intraperitoneally (single 
dose per day) to the animals in the respective groups for the last 14 days 
in the 3 weeks period. Chronic restraint stress was given for 4 hrs per 
day starting from day 0 to day 21 for all groups.
The body weight and food intake (both 24 hrs and 12 hrs dark 
phase) were measured at 0, 7, 14, 21 days in each group [12]. After 
acclimatizing to individual housing for12 hrs, food intake namely the 
24 hrs and 12 hrs dark phase food intake were measured by keeping 
pre-weighed amount of food in each of the cages, in which the animals 
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were individually housed and measuring the left-over food at the end of 
light phase (12 hrs) and dark phase (12 hrs). An accurate measurement 
was made by returning the spilled food at the bottom of the cage before 
measuring the weight of left-over food. Each animal was weighed and 
the body weight was recorded before the measurement of food intake 
on 0, 7, 14, and 21 days (Fig. 1).
RESULTS
All data ware entered into excel and analyzed using SPSS software 
version 19. At baseline, a one way ANOVA test done showed that there 
was no significant difference in either the body weight (p=0.08) or the 
food intake, both the 12 hrs (p=0.53) and 24 hrs (p=0.05) in the four 
groups of animals indicating that there was no significant difference at 
baseline among the animals which were randomized to the four groups.
The food intake, both 12 hrs and 24 hrs in both the treatment groups 
(low dose and high dose) as well as the standard trazodone group 
showed an increase when compared between the 7th day intake and 
21st day intake demonstrating the effects of drug treatment (Figs. 2 
and 3). Using paired t-test, both 12 hrs (p=0.011) and 24 hrs (p<0.001) 
food intake in the high dose agomelatine group were found to be 
significantly increased. In addition, between groups analyses using 
ANOVA test showed a statistically significant increased food intake 
only in group 2 treated with high dose agomelatine when compared to 
control, but not the other two groups (Table 1).
A paired t-test done at the end of 7 days showed that there was a 
statistically	significant	reduction	in	weight	in	Groups	1-3	(Fig.	4)	which	
were subsequently treated with low dose agomelatine, high dose 
agomelatine and trazodone respectively. The reduction in weight was 
induced as a result of the chronic restraint stress in this animal model.
A paired t-test between the body weight measurements on day 7 and 
day 21 was done to detect a statistically significant change in mean 
body weight when agomelatine/trazodone was given along with the 
restraint stress. The low dose agomelatine group showed a statistically 
significant reduction in body weight (p=0.026). However, using ANOVA 
test, the changes in mean body weight were not significant in the 
groups which were treated with low dose agomelatine or trazodone 
compared to the control group (Fig. 4 and Table 1). The rise in mean 
body weight in the group treated with high dose agomelatine (p=0.001) 
when compared to control, was statistically significant indicating 
that agomelatine at 50 mg/kg was effective in antagonizing the body 
weight lowering effect of restraint stress. This was also mirrored in the 
statistical analysis of food intake between the three groups done at the 
end of 21 days (Table 1).
DISCUSSION
Agomelatine is a MT receptor agonist, serotonin receptor 5HT2C 
antagonist and an effective chronobiotic agent. It has been found to 
be an effective antidepressant and an anxiolytic [6]. Agomelatine 
synchronizes the circadian rhythm and also ameliorates stress-related 
changes like depressive symptoms by modulating the cytoskeleton 
micro tubular dynamics and synaptic markers such as brain derived 
neurotrophic factor in amygdala and hippocampus [13,14]. Agomelatine 
antagonizes serotonin 2C receptor which is an important mediator of 
satiety [15]. It is well established from studies conducted earlier that 
restraint stress model in mice induces depression such as state in 
addition to the reduction in body weight and food intake by altered 
expression of food related genes like decreased ghrelin and increased 
Pro-opiomelanocortin [16,17].
A statistically significant increase in food intake was demonstrated 
only in the group treated with high dose agomelatine when compared 
Fig. 1: Methodology of the study
Fig. 2: Comparison of 12 hrs mean food intake among groups
Fig. 3: Comparison of 24 hrs mean food intake among groups
Fig. 4: Comparison of body weight (grams) among groups
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to control, but not in groups which were treated with low dose 
agomelatine and trazodone (Table 1). This has confirmed that though 
there was an increased food intake evident in all the three groups, it was 
the high dose agomelatine which has significantly increased the food 
intake higher than that of the control group at the end of the treatment 
period, thereby effectively neutralizing the effect of restraint stress 
on the body weight. This also explains why the high dose agomelatine 
group had mean body weight significantly higher compared to that of 
control in contrary to the low dose agomelatine and trazodone groups.
The reasons for the effects of agomelatine on body weight and 
food intake are twofold. The first being the antidepressant activity 
of the drug, responsible for the therapeutic effect on the animals 
in depression-like state induced by chronic restraint stress which 
secondarily has led to the changes in body weight and improved food 
intake in the stressed animals. Second, this can be explained as due 
to the agomelatine’s action at the serotonin receptor 5HT2C, which 
is a serotonin receptor subtype that is involved in normal satiation 
following a meal. Agomelatine antagonizes the 5HT2C receptor, and 
thereby it interferes with the satiety, increasing the food intake in the 
treated animals. The effect was well manifested in the group treated 
with high dose agomelatine. In contrast, the low dose agomelatine 
group did not show a similar response which probably could have been 
due to inadequate dosage to demonstrate such effects on weight and 
food intake. Thus, this study has delineated the effects of agomelatine 
on food intake and body weight when used as an antidepressant.
CONCLUSION
This study highlights the additional therapeutic benefit of agomelatine 
in the treatment of depression as it improves the altered feeding and 
body weight changes. The study clearly indicates the role of agomelatine 
in normalizing food intake and body weight in depressed patients with 
weight loss from poor feeding. These beneficial effects can be explained 
by its synchronizing action on circadian rhythm and antagonism of 
5HT2C receptor, an important mediator of satiety.
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Table 1: Between‑groups analysis using one‑way ANOVA
Groups 12 hrs food intake 24 hrs food intake Body weight
F statistic p value F statistic p value F statistic p value
Group	1	(low	dose	agomelatine) 7.091 0.073 7.606 0.140 10.051 0.205
Group	2	(high	dose	agomelatine) 0.000 0.000 0.001
Group	3	(trazodone) 0.275 0.321 0.176
